Nevanimibe ( DrugBank: Nevanimibe )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 75 | クッシング病 | 1 |
| 81 | 先天性副腎皮質酵素欠損症 | 3 |
75. クッシング病
臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-002240-17-GB (EUCTR) | 16/05/2017 | 06/03/2017 | A Study of ATR-101 for the Treatment of Cushing’s Syndrome | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | endogenous Cushing’s syndrome MedDRA version: 20.0;Level: SOC;Classification code 10014698;Term: Endocrine disorders;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: ATR-101; CI-984 | Millendo Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 16 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;United Kingdom |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004878-34-FR (EUCTR) | 18/09/2018 | 24/04/2018 | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Nevanimibe Hydrochloride Product Code: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: CI-984, 17AA70, PD 132301-2 | Millendo Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France;Spain;Brazil;Israel | ||
| 2 | EUCTR2017-004878-34-ES (EUCTR) | 01/08/2018 | 21/05/2018 | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Nevanimibe Hydrochloride Product Code: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: CI-984, 17AA70, PD 132301-2 | Millendo Therapeutics US, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France;Brazil;Spain;Israel | ||
| 3 | NCT03669549 (ClinicalTrials.gov) | July 11, 2018 | 10/9/2018 | Nevanimibe HCl for the Treatment of Classic CAH | A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | Drug: Nevanimibe hydrochloride | Millendo Therapeutics US, Inc. | NULL | Terminated | 18 Years | 80 Years | All | 15 | Phase 2 | Brazil;Czechia;France;Israel;Spain |